Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer

Carroll, Marissa C.; Morgan, Sally A.; Yarnold, John; Hill, Jennifer; Wright, Nikita

doi:10.1016/0277-5379(86)90144-6

Cited by 37 publications

(11 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients will be deemed suitable for radical radiotherapy, but in the majority, advanced disease within the chest or metastatic disease will preclude potentially curative treatment. For these patients, palliative radiotherapy may be considered, or supportive care alone [5,6].…”

mentioning

confidence: 99%

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales

Crook¹,

Duffy²,

Girling³

et al. 1997

Eur Respir J

View full text Add to dashboard Cite

Six hundred and ninety eight (85%) of the 821 clinicians responded. For Case 1, 74% would not recommend any adjuvant treatment, 24% would recommend radiotherapy, and <1% chemotherapy, and there was little expectation that adjuvant treatment would improve survival. For Case 2, 68% would recommend radiotherapy, 11% chemotherapy, and 1% surgery, 7% recommending a combination. Adjuvant treatment, regardless of modality, was expected to improve survival. For Case 3, only 11% would recommend chemotherapy, but 26% if the patient was aged ≤50 yrs. There was little expectation of survival beyond 1 yr, or of improving survival with chemotherapy. For all three cases, most of those not recommending chemotherapy would require it to achieve substantially improved survival for them to use it routinely.Surgery alone is currently considered sufficient for resectable non-small cell lung cancer. Chemotherapy is rarely recommended for disease of any stage.

show abstract

mentioning

confidence: 99%

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales

Crook¹,

Duffy²,

Girling³

et al. 1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…For these patients, the aim of treatment is primarily palliative. In the 1980s and for most of the 1990s, there was substantial disagreement, both nationally and internationally, about the role of chemotherapy in addition to palliative radiotherapy and active supportive care (Carroll et al , 1986; Aisner and Belani, 1993; SMAC, 1994). …”

Section: Treatment Of Lung Cancer Between 1985 and 2000mentioning

confidence: 99%

Survival from lung cancer in England and Wales up to 2001

Zee

Eisen

2008

Br J Cancer

View full text Add to dashboard Cite

“…This trial was designed to investigate and compare immediate versus delayed thoracic radiotherapy in patients with inoperable NSCLC, as there exists some doubt as to the clinical beneÿt of immediate radiotherapy for those patients with NSCLC (Carroll et al [10], Crook et al [11]). Articles by Phillips and Miller [12] and Cox et al [13] advocate immediate thoracic radiotherapy, suggesting that one may achieve a prolonged survival and may also improve a patient's quality of life.…”

Section: A Trial Of Radiotherapy In Non-small Cell Lung Cancermentioning

confidence: 99%

Estimating a treatment effect in survival studies in which patients switch treatment

Branson

Whitehead

2002

Statistics in Medicine

View full text Add to dashboard Cite

For disease indications such as Acquired Immune Deficiency Syndrome (AIDS) and various cancers, randomization to a pure control treatment may be scientifically desirable but not ethically acceptable. Clinicians may insist that the experimental treatment be made available, at least as a rescue medication, for all patients in the control arm. A method for estimating a treatment effect in survival data from randomized clinical trials of this type is developed under an accelerated failure time model. This approach retains all patients in the groups to which they were randomized and is not based on an ad hoc subgroup analysis. By conditioning on having observed patient switch times, this method avoids the need to model patient switching patterns in the analysis. This new approach is evaluated using simulation studies, and is illustrated through analysing data from a Medical Research Council lung cancer trial.

show abstract

Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer

Cited by 37 publications

References 2 publications

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales

Survival from lung cancer in England and Wales up to 2001

Estimating a treatment effect in survival studies in which patients switch treatment

Contact Info

Product

Resources

About